Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#238 of 388

Yi Chen

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2020No new ratings since Jul 2025

Analyst rating accuracy & track record

Yi Chen is an equity research analyst at HC Wainwright & Co.. Quantellect has scored 224 of their stock calls across 31 companies. Their picks beat their sector 34% of the time over the next 12 months, and their price targets were reached 20% of the time within a year.

Win % vs sector
34%
PT Hit % (12mo)
20%
Avg sector-excess
−9.1%
Scored calls
224
Tickers
31
Tier
Established

Track record

Quantellect has scored 224 of Yi Chen's stock calls across 31 companies, dating back to 2020. Their rated stocks beat their own sector 34% of the time over the next 12 months. On a typical call, a Chen pick returned −9.1% more than its sector over the following year.

Of the scored calls, 224 were bullish (Buy). Most of their coverage sits in Unknown. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ANGOAngioDynamics Inc
Buy$16.00Jul 2025+38.3%Miss
BLTEBelite Bio Inc ADR
Buy$100.00Jul 2025+140.6%Hit
EDSAEdesa Biotech Inc
Buy$5.00Jun 2025+257.0%Hit
LPCNLipocine Inc
Buy$8.00Jun 2025−42.0%Hit
ELDNEledon Pharmaceuticals Inc
Buy$9.00Jun 2025+29.9%Miss
LPCNLipocine Inc
Buy$8.00Jun 2025−54.6%Hit
LPCNLipocine Inc
Buy$8.00May 2025−48.1%Hit
EYPTEyePoint, Inc
Buy$22.00May 2025+72.9%Miss
OCULOcular Therapeutix Inc
Buy$15.00May 2025−2.2%Hit
KALAKala Pharmaceuticals Inc
Buy$12.00May 2025−113.3%Hit
VANIVivani Medical Inc.
Buy$4.00May 2025−11.3%Miss
SMTISanara Medtech Inc
Buy$53.00May 2025−44.1%Miss
BLTEBelite Bio Inc ADR
Buy$100.00May 2025+111.1%Hit
OKYOOKYO Pharma Ltd ADR
Buy$7.00May 2025−2.7%Miss
BLCOBausch + Lomb Corp
Buy$15.00May 2025+36.7%Hit
DRTSAlpha Tau Medical Ltd
Buy$9.00Apr 2025+184.4%Miss
GLSIGreenwich Lifesciences Inc
Buy$39.00Apr 2025+127.9%Miss
VANIVivani Medical Inc.
Buy$4.00Apr 2025+13.4%Miss
VNRXVolitionrx Ltd
Buy$2.50Apr 2025−96.7%Miss
BNGOBionano Genomics Inc
Buy$10.00Apr 2025−86.3%Miss
VNRXVolitionrx Ltd
Buy$2.50Apr 2025−89.2%Miss
OPKOpko Health Inc
Buy$3.00Apr 2025−32.0%Miss
ANGOAngioDynamics Inc
Buy$16.00Apr 2025−4.4%Miss
KALAKala Pharmaceuticals Inc
Buy$15.00Apr 2025−106.1%Hit
VANIVivani Medical Inc.
Buy$4.00Apr 2025−1.9%Miss
SRTSSensus Healthcare Inc
Buy$12.00Apr 2025−16.3%Miss
VRAXVirax Biolabs Group Limited Ordinary Shares
Buy$3.00Mar 2025−84.1%Miss
ICCMIcecure Medical
Buy$2.50Mar 2025−75.9%Miss
KPRXKiora Pharmaceuticals Inc
Buy$10.00Mar 2025−37.5%Miss
SMTISanara Medtech Inc
Buy$51.00Mar 2025−44.6%Miss
VANIVivani Medical Inc.
Buy$4.00Mar 2025−8.4%Miss
ANIXAnixa Biosciences Inc
Buy$7.00Mar 2025−17.1%Miss
RGNXRegenxbio Inc
Buy$34.00Mar 2025−4.3%Miss
RGNXRegenxbio Inc
Buy$34.00Mar 2025−2.6%Miss
OPKOpko Health Inc
Buy$3.00Mar 2025−37.2%Miss
BLTEBelite Bio Inc ADR
Buy$100.00Mar 2025+136.4%Hit
DRTSAlpha Tau Medical Ltd
Buy$9.00Mar 2025+182.0%Miss
VANIVivani Medical Inc.
Buy$4.00Mar 2025−4.3%Miss
OPKOpko Health Inc
Buy$3.00Mar 2025−38.8%Miss
EYPTEyePoint, Inc
Buy$22.00Mar 2025+116.8%Miss
OCULOcular Therapeutix Inc
Buy$15.00Mar 2025+47.6%Hit
OPKOpko Health Inc
Buy$3.00Mar 2025−45.7%Miss
ANIXAnixa Biosciences Inc
Buy$7.00Feb 2025−8.5%Miss
OKYOOKYO Pharma Ltd ADR
Buy$7.00Feb 2025+55.0%Miss
OKYOOKYO Pharma Ltd ADR
Buy$7.00Feb 2025+49.7%Miss
KALAKala Pharmaceuticals Inc
Buy$15.00Feb 2025−106.0%Hit
GLSIGreenwich Lifesciences Inc
Buy$38.00Feb 2025+122.6%Miss
OKYOOKYO Pharma Ltd ADR
Buy$7.00Feb 2025+83.5%Miss
SRTSSensus Healthcare Inc
Buy$12.00Feb 2025−25.4%Miss
SMTISanara Medtech Inc
Buy$50.00Jan 2025−52.5%Miss
Go to

Yi Chen: analyst track record FAQ

Is Yi Chen a good stock analyst?

Yes, by track record. Yi Chen ranks number 238 of 388 of the analysts Quantellect scores, with a Q Score of 23 out of 100. Past results do not guarantee future ones.

What is Yi Chen's win rate?

Yi Chen's win rate is 34%. Across 224 scored calls, their rated stocks beat their sector 34% of the time over the next 12 months. On a typical call they returned −9.1% more than the sector.

What stocks and sectors does Yi Chen cover?

Yi Chen covers 31 companies, with the most coverage in Unknown. See the ratings table above for every scored call and its outcome.

Are Yi Chen's price targets accurate?

Yi Chen's price targets are reached within 12 months 20% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Yi Chen's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Yi Chen rank among Wall Street analysts?

Yi Chen ranks number 238 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.